Trial Profile
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN 3 - vs. QW GLP-1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN-3
- Sponsors Novo Nordisk
- 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results of post-hoc analysis of SUSTAIN1-5 & 7-10 presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 29 Jun 2021 Results (n=5680) of post-hoc analysis of data from SUSTAIN 2-4, 7,8,10 studies presented at the 81st Annual Scientific Sessions of the American Diabetes Association